Ginkgo Bioworks operates a platform for cell programming and synthetic biology, engineering microorganisms for customers across pharmaceuticals, agriculture, food, and industrial chemicals, and offers biosecurity services.
| Filer | 13FScore | This quarter | Shares | Value | % of their book |
|---|---|---|---|---|---|
| SB INVESTMENT ADVISERS (UK) LTD (auto-surfaced) | 22 | Holds (flat) | 610,729 | $6,052,324 | 0.1% |
| a16z Capital Management, L.L.C. (auto-surfaced) | 92 | Holds (flat) | 108,568 | $1,075,909 | 0.0% |
| Paul Tudor Jones / Tudor | 62 | Trimmed -28% | 335,710 | $3,326,886 | 0.0% |
| Report | Date | Stance |
|---|---|---|
| #134 — Citrini Therapeutics: We Wanted to Use Claude to Create a New Drug | 2026-10-20 | WATCH |
Every tracked holder of this name, sorted new → added → flat → trimmed. Shares = reported 13F share count; Value as reported (a few managers file values in $thousands). Generated 2026-10-17.